enGene names Michael Heffernan board chairman as Richard Glickman steps down

• enGene named Michael Heffernan chairman, replacing Dr. Richard Glickman, who is stepping down after more than 14 years in the role.
• Heffernan joined the board in July 2025; he founded Collegium Pharmaceutical, serving as president, CEO, chairman.
• Board shift aligns with planned pre-BLA FDA meeting in 2H 2026, targeted BLA start in 2H 2026, potential 2027 approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607160800BIZWIRE_USPR_____20260716_BW174001) on July 16, 2026, and is solely responsible for the information contained therein.